CN104411339A - 含功能性microRNA/siRNA的细胞微粒子及其应用 - Google Patents

含功能性microRNA/siRNA的细胞微粒子及其应用 Download PDF

Info

Publication number
CN104411339A
CN104411339A CN201380032773.1A CN201380032773A CN104411339A CN 104411339 A CN104411339 A CN 104411339A CN 201380032773 A CN201380032773 A CN 201380032773A CN 104411339 A CN104411339 A CN 104411339A
Authority
CN
China
Prior art keywords
mir
microrna
sirna
feature
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201380032773.1A
Other languages
English (en)
Other versions
CN104411339B (zh
Inventor
张辰宇
曾科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Micromedmark Biotech Co Ltd
Original Assignee
Micromedmark Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromedmark Biotech Co Ltd filed Critical Micromedmark Biotech Co Ltd
Priority to CN201380032773.1A priority Critical patent/CN104411339B/zh
Publication of CN104411339A publication Critical patent/CN104411339A/zh
Application granted granted Critical
Publication of CN104411339B publication Critical patent/CN104411339B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)

Abstract

本发明涉及含功能性microRNA/siRNA的细胞微粒子及其应用。具体地，本发明公开了一种功能性microRNA和/或siRNA的用途，用于制备施用于哺乳动物的组合物，施用所述组合物后在动物体内的第一部位中形成细胞微粒子，并运送到第二部位，从而改善第二部位的生理状态或治疗第二部位的疾病，其中第二部位不同于第一部位。所述用途有利于优化功能性microRNA和/或siRNA的给药方式。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201380032773.1A 2012-06-21 2013-06-21 表达、分泌及运输功能性microRNA/siRNA的方法及其应用 Active CN104411339B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201380032773.1A CN104411339B (zh) 2012-06-21 2013-06-21 表达、分泌及运输功能性microRNA/siRNA的方法及其应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2012102126908 2012-06-21
CN201210212690.8A CN103505743A (zh) 2012-06-21 2012-06-21 含功能性microRNA/siRNA的细胞微粒子及其应用
CN201380032773.1A CN104411339B (zh) 2012-06-21 2013-06-21 表达、分泌及运输功能性microRNA/siRNA的方法及其应用
PCT/CN2013/077705 WO2013189309A1 (zh) 2012-06-21 2013-06-21 含功能性microRNA/siRNA的细胞微粒子及其应用

Publications (2)

Publication Number Publication Date
CN104411339A true CN104411339A (zh) 2015-03-11
CN104411339B CN104411339B (zh) 2020-11-17

Family

ID=49768129

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201210212690.8A Pending CN103505743A (zh) 2012-06-21 2012-06-21 含功能性microRNA/siRNA的细胞微粒子及其应用
CN201380032773.1A Active CN104411339B (zh) 2012-06-21 2013-06-21 表达、分泌及运输功能性microRNA/siRNA的方法及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201210212690.8A Pending CN103505743A (zh) 2012-06-21 2012-06-21 含功能性microRNA/siRNA的细胞微粒子及其应用

Country Status (4)

Country Link
US (1) US10308932B2 (zh)
EP (1) EP2865393B1 (zh)
CN (2) CN103505743A (zh)
WO (1) WO2013189309A1 (zh)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108310381A (zh) * 2017-01-16 2018-07-24 昆山彭济凯丰生物科技有限公司 通过miR-6511b-3p进行抗癌的方法和药物及其应用
CN108690846A (zh) * 2018-04-17 2018-10-23 上海大学 抑制MiR-29b基因表达的应用
CN108866195A (zh) * 2018-08-17 2018-11-23 柳州市工人医院 miR-3942-5p作为肿瘤标志物在制备无创型泛癌诊断及预后药物中的应用
CN109750096A (zh) * 2019-01-17 2019-05-14 华中科技大学同济医学院附属同济医院 抑制agxt基因表达引起草酸性结石的分子机制及预警方法
CN109837306A (zh) * 2019-03-20 2019-06-04 江南大学附属医院（无锡市第四人民医院） 包载miRNA-204-5p的外泌体及其制备方法和应用
CN110408703A (zh) * 2019-08-15 2019-11-05 河北仁博科技有限公司 结直肠癌miRNA标志物及其应用
CN110433171A (zh) * 2019-08-20 2019-11-12 中山大学附属第六医院 miRNA-1293在制备抗结直肠肿瘤药物中的应用
CN110652522A (zh) * 2019-10-16 2020-01-07 华中科技大学同济医学院附属同济医院 miR-2052在制备抗肝癌药物中的应用
CN110669844A (zh) * 2019-11-15 2020-01-10 复旦大学附属中山医院 一种用于检测培美曲塞+顺铂治疗适用性的试剂盒
CN112843084A (zh) * 2019-11-27 2021-05-28 中国人民解放军第四军医大学 MiR-122-5p在制备促进创伤愈合药物中的应用
CN114214422A (zh) * 2020-03-30 2022-03-22 中国医学科学院肿瘤医院 用于肺癌诊断的试剂盒、装置及方法
CN114480672A (zh) * 2022-02-22 2022-05-13 青岛农业大学 一种通过miR-145筛选高产肉率碱地黑牛的方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015133522A1 (ja) * 2014-03-04 2015-09-11 国立大学法人大阪大学 大腸癌の治療剤、及び大腸癌患者の予後の予測方法
CN106177990B (zh) * 2014-11-17 2020-08-28 江苏命码生物科技有限公司 一种新的前体miRNA及其在肿瘤治疗中的应用
KR101862080B1 (ko) * 2015-02-25 2018-07-04 (주)바이오니아 마이크로 rna 를 유효 성분으로 포함하는 암 치료용 약학 조성물
US9856481B2 (en) * 2015-08-13 2018-01-02 Ann & Robert H. Lurie Children's Hospital MicroRNA treatment of fibrosis
CN105664163B (zh) * 2016-02-01 2019-02-05 固安博健生物技术有限公司 mir-5010及其成熟miRNA在制备骨肉瘤诊疗制剂的应用
CN107400730B (zh) * 2017-09-26 2018-08-31 合肥金域医学检验所有限公司 一种用于检测肺癌的试剂盒
WO2019103578A1 (ko) * 2017-11-27 2019-05-31 (주)프로스테믹스 올리고뉴클레오티드 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
CN108424961B (zh) * 2018-05-21 2022-03-15 浙江中医药大学 一种用于检测上火的血清特异性miRNA的试剂盒及其应用
CN108707625B (zh) * 2018-07-03 2021-09-21 云笛生物科技有限公司 mir-124和HER2-shRNA双基因表达盒病毒载体、构建方法、病毒、应用
CN109706239A (zh) * 2018-09-26 2019-05-03 南京市妇幼保健院 一种miR-1976在防治细菌性阴道病中的应用
CN109554392A (zh) * 2018-12-18 2019-04-02 西北农林科技大学 一种牛mir-145基因过表达重组腺病毒载体的构建方法
WO2020246380A1 (ja) * 2019-06-05 2020-12-10 株式会社キャンサーステムテック 癌治療剤
CN110438225B (zh) * 2019-07-25 2023-05-12 上海交通大学医学院附属新华医院 一种肿瘤迁移侵袭能力和/或增殖能力评价试剂盒
CN110699443A (zh) * 2019-10-21 2020-01-17 无锡市第二人民医院 hsa-miR-378i作为标志分子在制备诊断结核病试剂盒中的用途及其检测试剂盒
CN114875142A (zh) * 2020-03-30 2022-08-09 中国医学科学院肿瘤医院 包括外泌体miR-106b-3p、miR-550-5p等在肺癌诊断中的应用
US20220119812A1 (en) * 2020-10-20 2022-04-21 Duquesne University Of The Holy Spirit Micro rna interactions as therapeutic targets for covid-19 and other viral infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101386848A (zh) * 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
CN101869715A (zh) * 2010-05-26 2010-10-27 江苏命码生物科技有限公司 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用
CN102218144A (zh) * 2010-04-13 2011-10-19 江苏命码生物科技有限公司 一种调节生物体内微小核糖核酸含量的方法及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2002003T3 (en) * 2005-05-27 2016-03-21 Ospedale San Raffaele Srl Gene vector comprising miRNA
RU2010117178A (ru) * 2007-10-01 2011-11-10 Алькон Рисерч, Лтд. (Us) Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний
US20110009469A1 (en) * 2007-12-05 2011-01-13 The Johns Hopkins University Compositions and methods of treating neoplasia
CN103260647A (zh) * 2010-11-30 2013-08-21 伦敦健康科学中心研究公司 用于治疗心脏病的egfr拮抗剂
US20130259926A1 (en) * 2012-03-28 2013-10-03 Gradalis, Inc. BI-FUNCTIONAL shRNA TARGETING MESOTHELIN AND USES THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101386848A (zh) * 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
CN102218144A (zh) * 2010-04-13 2011-10-19 江苏命码生物科技有限公司 一种调节生物体内微小核糖核酸含量的方法及其用途
CN101869715A (zh) * 2010-05-26 2010-10-27 江苏命码生物科技有限公司 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108310381A (zh) * 2017-01-16 2018-07-24 昆山彭济凯丰生物科技有限公司 通过miR-6511b-3p进行抗癌的方法和药物及其应用
CN108690846A (zh) * 2018-04-17 2018-10-23 上海大学 抑制MiR-29b基因表达的应用
CN108866195A (zh) * 2018-08-17 2018-11-23 柳州市工人医院 miR-3942-5p作为肿瘤标志物在制备无创型泛癌诊断及预后药物中的应用
CN109750096A (zh) * 2019-01-17 2019-05-14 华中科技大学同济医学院附属同济医院 抑制agxt基因表达引起草酸性结石的分子机制及预警方法
CN109837306A (zh) * 2019-03-20 2019-06-04 江南大学附属医院（无锡市第四人民医院） 包载miRNA-204-5p的外泌体及其制备方法和应用
CN110408703B (zh) * 2019-08-15 2022-02-22 河北仁博科技有限公司 结直肠癌miRNA标志物及其应用
CN110408703A (zh) * 2019-08-15 2019-11-05 河北仁博科技有限公司 结直肠癌miRNA标志物及其应用
CN110433171A (zh) * 2019-08-20 2019-11-12 中山大学附属第六医院 miRNA-1293在制备抗结直肠肿瘤药物中的应用
CN110652522A (zh) * 2019-10-16 2020-01-07 华中科技大学同济医学院附属同济医院 miR-2052在制备抗肝癌药物中的应用
CN110669844A (zh) * 2019-11-15 2020-01-10 复旦大学附属中山医院 一种用于检测培美曲塞+顺铂治疗适用性的试剂盒
CN110669844B (zh) * 2019-11-15 2022-08-12 复旦大学附属中山医院 一种用于检测培美曲塞+顺铂治疗适用性的试剂盒
CN112843084A (zh) * 2019-11-27 2021-05-28 中国人民解放军第四军医大学 MiR-122-5p在制备促进创伤愈合药物中的应用
CN114214422A (zh) * 2020-03-30 2022-03-22 中国医学科学院肿瘤医院 用于肺癌诊断的试剂盒、装置及方法
CN114214422B (zh) * 2020-03-30 2023-06-27 中国医学科学院肿瘤医院 外泌体miR-106b-3P、ARPC5在肺癌诊断中的应用
CN114480672A (zh) * 2022-02-22 2022-05-13 青岛农业大学 一种通过miR-145筛选高产肉率碱地黑牛的方法
CN114480672B (zh) * 2022-02-22 2023-08-15 青岛农业大学 一种通过miR-145筛选高产肉率碱地黑牛的方法

Also Published As

Publication number Publication date
CN104411339B (zh) 2020-11-17
US20160017321A1 (en) 2016-01-21
WO2013189309A1 (zh) 2013-12-27
EP2865393A4 (en) 2016-03-23
US10308932B2 (en) 2019-06-04
EP2865393B1 (en) 2019-08-07
EP2865393A1 (en) 2015-04-29
CN103505743A (zh) 2014-01-15

Similar Documents

Publication Publication Date Title
CN104411339B (zh) 表达、分泌及运输功能性microRNA/siRNA的方法及其应用
CN102218144B (zh) 一种调节生物体内微小核糖核酸含量的方法及其用途
US20230115116A1 (en) Oncolytic viral vectors and uses thereof
US11612625B2 (en) Oncolytic viral vectors and uses thereof
CN108463561B (zh) 用于诊断、预后和治疗监测基于神经性、神经退行性和炎症的疾病的包含基于微rna的小神经胶质细胞微泡的方法
US9821009B2 (en) Method for modulating microRNA content in living beings and the use thereof
Słotwiński et al. MicroRNAs in pancreatic cancer diagnosis and therapy
ES2446362T3 (es) Huellas de microARN durante megacariocipoyesis humana
ES2536422T3 (es) Métodos y composiciones basados en microARN para el diagnóstico y tratamiento de cáncer pancreático
CN107108686A (zh) 用于恶性肿瘤的rna干扰组合物和方法
JP2009507918A5 (zh)
US20210038732A1 (en) Anticancer microrna and lipid formulations thereof
Hwang et al. Exosomal microRNAs as diagnostic and therapeutic biomarkers in non-malignant liver diseases
CN107213471A (zh) 一种用于肝癌与肝癌微环境相互作用的新的长链非编码rna检测及其应用
Zandieh et al. Epigenetic regulation of autophagy by non-coding RNAs in gastrointestinal tumors: Biological functions and therapeutic perspectives
Feng et al. Mesenchymal stem cell-derived exosomes as delivery vehicles for non-coding RNAs in lung diseases
CN110075122A (zh) 一种肝癌治疗性外泌体药物
CN105617401B (zh) miRNA的肿瘤辐射增敏及减弱辐射旁效应作用、实施方法及用途
Sheervalilou et al. A review on microRNAs’ function, detection and evaluation methods, expression dysregulation mechanisms and possible applications in clinical phase as diagnostic, prognostic and therapeutic biomarkers of lung cancer patients
Karolina et al. micro RNAs as Therapeutic Agents and Targets
CN106860877A (zh) 一种利用microRNA提高抗肿瘤药物敏感性的应用
Tsai et al. Enhancement of gene therapy on hepatocellular carcinoma by sonoporation--parameter studies
CN102716498A (zh) 一种可高效高特异灭杀p53基因突变型乳腺癌细胞的药物脂质体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant